CK2 Inhibitors – New CK2 Kinase Inhibitors for antineoplastic drugs and diagnostics

Beside cardiovascular diseases, malignant tumours take

the second place in cause of human death. Neoplastic diseases are indicated by a high cell proliferation. The inhibition of this cell proliferation by an active agent in a medicament is a worldwide accepted approach for tumour therapy. Protein kinase CK2 belongs together with others to the group of second-messenger independent kinases. Despite of unambiguous references for the involvement of CK2 in malignant transformation, tumour origin and progression, there are only a few effective inhibitors for this enzyme on-hand. This invention provides access to a novel class of potent human CK2 kinase inhibitors. The disclosed compounds can be used as active ingredients e.g. for the treatment of neoplastic diseases. Further, the patent application discloses synthesis of the compounds with optimised product yield.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Building lighter with concrete

How concrete 3D printing saves material and CO2. “As soon as climate compatibility comes into play we have to look at mineral building materials. And this is where the really…

Optical cavities could provide new technological possibilities

Light and molecules behave in very special ways in optical cavities. Don’t think this is important to you? It may be soon. A research team from the Norwegian University of…

Finding superconductivity in nickelates

Arizona State physicist uses intuition, supercomputers to identify new high-temperature superconductor. The study of superconductivity is littered with disappointments, dead-ends, and serendipitous discoveries, according to Antia Botana, professor of physics at…

Partners & Sponsors